Antiviral ActivityALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.
Clinical Trial MilestonesThe initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.
Safety ProfileALG-000184 showed a favorable safety profile, with no viral breakthroughs or known CAM-resistant mutations reported with ALG-000184 monotherapy treatment.